



Date:- November 12, 2012

To,
The Chief Manager,
Listing Department
National Stock Exchange Limited
C/1, Block G, 5th Floor, Exchange Plaze,
Bandra Kurla Complex, Bandra (E),
Mumbai - 400 051.

Kind Attn: Mr. Rajesh Modani

Sub: Outcome of Board Meeting held on 12/11/2012

Ref.:- M/s Sharon Bio-Medicine Ltd., Scrip Code No. SHARONBIO.

Dear Sir,


Please find the outcome of Board Meeting of the company held on 12/11/2012 at its corporate office at Sharon House, Plot No. 163, Park Street, S.V.P. Nagar, Andheri (W), Mumbai - 400 053.

1. In compliance of clause 41 of Listing Agreement, we hereby attach unaudited financial results for the quarter ended September 30, 2012.
2. Copy of Auditors Limited Review Report for the Quarter ended 30th September, 2012.

This is for your information and records.

Thanking you,

Yours faithfully,
For Sharon Bio-Medicine Limited


M.P. Kala
Director

Regd. Off. & Works I : W-34 & 34/1, MIDC, Talaja, Dist-Raigad, Maharashtra (India).

Works II: Plot No. L-6, MIDC, Talaja, Dist-Raigad, Maharashtra (India)

Admin Office : 312, C Wing, BSEL Tech Park, Sector - 30(A), Vashi, Navi Mumbai - 400 705

Tel.: 91 22 - 67944000 Fax : 91 22 - 67944001

Head Office : Plot No. 163, Smt Janakidevi Public School Rd., SVP Nagar, Andheri (West), Mumbai - 400 053.

Tel. : 91 22 26323192 / 93 / 94 Fax : 26323140 E-mail : info@sharonbio.com

www.sharonbio.com

Caring for relationships



BIO-MEDICINE LTD.

ISO 9001 - 2008 Certified Company

**UNAUDITED STANDALONE FINANCIAL RESULTS (PROVISIONAL) FOR THE QUARTER
ENDED SEPTEMBER 30, 2012.**

(Rs. In Lacs)

SR. NO.	PARTICULARS	Quarter ended & year to the date			
		As on 30/09/2012	As on 30/06/2012	As on 30/09/2011	30/06/2012 (Audited)
1	Net Sales / Income from Operations	21,668.14	20,907.59	17,436.49	78,506.14
	Total Income	21,668.14	20,907.59	17,436.49	78,506.14
2	Total Expenditure				
	a) (Increase)/Decrease in Stock in Trade	(895.70)	(1,322.16)	(792.63)	(4,100.20)
	b) Consumption of Materials	14,978.86	15,409.60	12,395.68	54,143.31
	c) Purchases of Trading Goods	4,038.52	3,512.84	2,890.35	15,554.28
	d) Employees Cost	405.35	388.79	362.89	1,397.22
	e) Depreciation	226.11	201.51	246.92	886.38
	f) Other Expenditure	502.39	473.76	418.78	1,983.75
	Total	19,255.53	18,662.34	15,461.97	69,864.72
3	Profit from Operations before Exchange Rate Difference, Other Income, Interest & Exceptional Items (1 - 2)	2,412.61	2,245.25	1,974.52	8,641.42
4	Other Income	20.42	27.45	18.60	82.69
5	Profit from Operations before Interest & Exceptional Items (3 + 4)	2,433.03	2,272.70	1,993.12	8,734.11
6	Interest	980.25	882.79	821.52	3,425.97
7	Profit after Interest but before Exception items (5-6)	1,452.78	1,389.91	1,171.60	5,308.14
8	Exception Items	-	-	-	3.14
9	Profit (+)/Loss(-) from Ordinary Activities before tax (7-8)	1,452.78	1,389.91	1,171.60	5,305.00
10	Tax Expenses	255.30	205.15	202.81	1,143.56
11	Net Profit before ordinary activities (8 - 9)	1,197.48	1,184.76	968.79	4,161.44
12	Extra Ordinary Items (Net of Tax)	-	-	-	-
13	Net Profit after Taxes (10 - 11)	1,197.48	1,184.76	968.79	4,161.44
14	Paid up Equity Share Capital (Face value of Rs.10/- each)	1,055.69	1,055.69	1,055.69	1,055.69
15	Reserves excluding Revaluation Reserves	-	-	-	17,540.59
16	Earning Per Share				
	i) before extra ordinary items	11.34	11.22	9.18	40.18
	ii) after extra ordinary items	11.09	11.01	9.02	39.41

Part-II

SR. NO.	PARTICULARS	Quarter ended & Year to the date			30/06/2012 (Audited)
		As on 30/09/2012	As on 30/06/2012	As on 30/09/2011	
(A)	Aggregate of Public Shareholdings				
	No. of Shares	4,194,125	4,144,325	4,144,325	4,144,325
	Percentage of Shareholdings	39.73%	39.26%	39.26%	39.26%
17	Promoters & promoter group Shareholding				
	a) Pledged / Encumbered				
	- Number of Shares	744,500	1,145,360	883,800	1,145,360
	- Percentage of Shares	11.70%	17.86%	13.78%	16.71%
	(as a % of the total shareholding of promoter & promoter group)	7.05%	10.15%	8.37%	10.85%
	- Percentage of Shares				
	(as a % of the total share capital of the Company)				
	b) Non-encumbered				
	- Number of Shares	5,618,275	5,267,215	5,528,775	5,267,215
	- Percentage of Shares	88.30%	82.14%	86.22%	82.14%
	(as a % of the total shareholding of promoter & promoter group)	53.22%	49.89%	52.37%	49.89%
	- Percentage of Shares				
	(as a % of the total share capital of the Company)				

Notes:-

- The above results for the quarter ended September 30, 2012 have been reviewed by the Audit Committee and were taken on record by the Board of Directors in its meeting held on November 12, 2012.
- The "Limited Review" required under clause 41 of listing agreement has been done by statutory auditors of the Company.
- The Company has provided for Foreign Exchange (Loss)/Gains under Exception Items due to exchange differences arising during the periods on foreign currency contracts and borrowings including Foreign Currency Convertible Bonds and interest for the current quarter.
- Previous years figures have been regrouped and recast wherever necessary.
- Information on investor complaints for the quarter ended September 30, 2012 (in nos.)

Opening Balance of Complaints	Received during the Quarter	Disposed Off during the Quarter	Closing Balance
NIL	0	0	NIL

By order of the Board
For Sharon Bio-Medicine Ltd.

Navita
Savita Gowda
Managing Director.

Place : Mumbai.
Date : 12.11.2012

Regd. Off. & Works I : W-34 & 34/1, MIDC, Talaja, Dist-Raigad, Maharashtra (India),
Works II: Plot No. L-6, MIDC, Talaja, Dist-Raigad, Maharashtra (India)
Admin Office : 312, C Wing, BSEL Tech Park, Sector - 30(A), Vashi, Navi Mumbai - 400 705
Tel : 91 22 - 67944000. Fax : 91 22 - 67944001
Head Office : Plot No. 163, Smt Janakidevi Public School Rd., SVP Nagar, Andheri (West), Mumbai - 400 053.
Tel : 91 22 26323192 / 93 / 94 Fax : 26323140 E-mail : info@sharonbio.com

www.sharonbio.com

Caring for relationships

CA. S. C. Agrawal

B. Com., (Hons.) LL.B., F.C.A., DISA (ICAI)

Shyam C. Agrawal & Co.**Chartered Accountants**

3/63, Nityanand Nagar, Vibhag IV,

Sahar Road, Andheri (East),

Mumbai - 400 069.

Tel. : (O) 2684 0916 • Tele Fax : 2683 5699

E-mail : shyam31774@yahoo.com

REVIEW REPORT

We have reviewed the accompanying statement of unaudited financial results of M/s. Sharon Bio-Medicine Ltd., for the period ended on 30th September, 2012 except for the disclosures regarding 'Public Shareholding' and 'Promoter and Promoter Group Shareholding' which have been traced from disclosures made by the management and have not been audited by us. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors/ Committee of Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2400, engagements to Review Financial Statements issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards¹ and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of Clause 41 of the Listing Agreement including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Shyam C. Agrawal & Co
Chartered Accountants

Shyam C. Agrawal
(Proprietor)

Date: 12/11/2012
Place: Mumbai.

